Combining CSPG4-CAR and CD20-CCR for treatment of metastatic melanoma

The prognosis for patients with metastatic melanoma is poor and treatment options are limited. Genetically-engineered T cell therapy targeting chondroitin sulfate proteoglycan 4 (CSPG4), however, represents a promising treatment option, especially as both primary melanoma cells as well as metastases...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Frontiers in immunology Jg. 14; S. 1178060
Hauptverfasser:	Teppert, Karin, Winter, Nora, Herbel, Vera, Brandes, Caroline, Lennartz, Simon, Engert, Fabian, Kaiser, Andrew, Schaser, Thomas, Lock, Dominik
Format:	Journal Article
Sprache:	Englisch
Veröffentlicht:	Frontiers Media S.A 11.10.2023
Schlagworte:	adoptive T cell therapy chimeric antigen receptor chimeric costimulatory receptor Immunology immunotherapy melanoma
ISSN:	1664-3224, 1664-3224
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!